logo
logo
Sign in

Recombinant Protein Market - North America to Remain Dominant in the Market

avatar
preet gambhir
Recombinant Protein Market - North America to Remain Dominant in the Market

A new report published by Fact.MR estimates the global recombinant protein market to witness expansion at a moderate CAGR during the forecast period 2017 to 2022. Revenues from the global recombinant protein market will reach nearly US$ 460 Mn by 2022-end.

Request for the Report Summary: https://www.factmr.com/report/186/recombinant-protein-market

Through genetic engineering, and cell engineering, recombinant protein are produced from creature body. The recombinant protein technology now stands at the edge of biotechnology production. Becoming the new standard, this technology is witnessing a gradual shift from bulk production procedure towards post-production techniques, which in turn promises an enhanced delivery and stability. The highly effective recombinant proteins play an integral part in treating specific diseases, such as hemophilia. However, blood coagulation factor is excluded, as it possesses an extremely limited source.

A large number of recombinant protein drugs utilized are human proteins. This is mainly to compensate functional proteins in vivo defects, and for increasing the functions of proteins in a body. These factors provide recombinant proteins with substantially higher safety as compared to small molecules, further leading towards higher approval rates.

The clinical trial periods for recombinant proteins are comparatively shorter than small molecule drugs, which further aids in enhancing patient protection, and renders pharmaceutical companies with a relatively longer exclusive sales time. Factors such as these are driving the development, and demand for recombinant proteins. Recombinant proteins target diseases such as cardiovascular diseases, endocrine diseases, viral diseases, and cancer. In addition, the global recombinant protein market has a larger extension space, with few approval drugs available without any alternative products in therapeutic areas. These factors might influence growth of the market over the forecast period. However, factors such as technical barriers, financial barriers have made recombinant protein technology expensive. Moreover, replication of recombinant proteins incurs many challenges, as compared to replication of small molecule chemicals. These factors may impede growth of the market in the near future.

Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=186

Basic research will remain the largest application segment in the global recombinant proteins market. Revenues from basic research will reach roughly US$ 270 Mn in revenues by the end of 2022. Toxicity screening, and drug discovery & development will witness the fastest expansion through 2022, based on application of recombinant proteins. Recombinant protein sales for forensic testing application will exhibit the lowest CAGR in the market through 2022.

Academic & research institutes will remain the most lucrative end-users in the global recombinant proteins market, accounting for more than one-third revenue share of the market throughout the forecast period. Biopharmaceutical companies will continue to be the fastest expanding end-users of recombinant proteins in the global market.

Key players identified in the global recombinant protein market include Thermo Fisher Scientific, Inc., Sigma Aldrich, Merck Millipore Limited, GenScript Corporation, Crown Bioscience, Inc., PerkinElmer, Inc., BPS Bioscience Inc., Bio-Rad Laboratories, Inc., A.M.S. Biotechnology (Europe) Limited, and Abcam plc.

Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=186

About Us

Fact.MR’s methodology is robust and comprehensive. We employ a range of tools and assets to develop an all-encompassing coverage of a range of industries. We compile data points at local, country, regional, and global level – our approach to capturing the finest nuances, without losing sight of the bigger picture helps us in developing accurate and reliable forecasts and estimates.

Fact.MR has a standard set of guidelines and standards that help maintain a level of consistency across all of our research offerings. The standardization includes step-by-step documentation of the methodologies and guidelines on the sources that are to be used for incorporation of objective and accurate data.

The standardization also involves use of industry-wide analytical tools, and rigorous quality checks to validate market forecasts and sizes. Our unwavering focus on standardization ensures that clients receive the same quality of research and analysis that Fact.MR is known for.

Contact Us

11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
E: [email protected]
Blog: https://theheraldmedia.com/

collect
0
avatar
preet gambhir
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more